Loading...
XNASGILD
Market cap116bUSD
Dec 23, Last price  
93.40USD
1D
0.90%
1Q
11.47%
Jan 2017
30.43%
Name

Gilead Sciences Inc

Chart & Performance

D1W1MN
XNAS:GILD chart
P/E
20.55
P/S
4.29
EPS
4.55
Div Yield, %
3.27%
Shrs. gr., 5y
-0.78%
Rev. gr., 5y
4.15%
Revenues
27.12b
-0.60%
1,324,621,0002,028,400,0003,026,139,0004,230,045,0005,335,750,0007,011,383,0007,949,420,0008,385,385,0009,702,517,00011,201,688,00024,890,000,00032,639,000,00030,390,000,00026,107,000,00022,127,000,00022,449,000,00024,689,000,00027,305,000,00027,281,000,00027,116,000,000
Net income
5.67b
+23.37%
449,371,000813,914,000-1,189,957,0001,615,298,0002,011,154,0002,635,755,0002,901,257,0002,803,637,0002,591,566,0003,074,808,00012,101,000,00018,108,000,00013,501,000,0004,628,000,0005,455,000,0005,386,000,00089,000,0006,225,000,0004,592,000,0005,665,000,000
CFO
8.01b
-11.75%
511,378,000715,080,0001,218,059,0001,765,398,0002,204,659,0003,080,054,0002,833,913,0003,639,010,0003,194,716,0003,104,988,00012,818,000,00020,329,000,00016,669,000,00011,898,000,0008,400,000,0009,144,000,0008,168,000,00011,384,000,0009,072,000,0008,006,000,000
Dividend
Sep 13, 20240.77 USD/sh
Earnings
Feb 04, 2025

Profile

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients. In addition, the company provides Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; Ranexa, an oral formulation for the treatment of chronic angina; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. Gilead Sciences, Inc. has collaboration agreements with Arcus Biosciences, Inc.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Tango Therapeutics, Inc.; Jounce Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Gadeta B.V.; Bristol-Myers Squibb Company; Dragonfly Therapeutics, Inc.; and Merck & Co, Inc. The company was incorporated in 1987 and is headquartered in Foster City, California.
URL
https://www.gilead.com/
IPO date
Jan 22, 1992
Employees
17,000
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
27,116,000
-0.60%
27,281,000
-0.09%
27,305,000
10.60%
Cost of revenue
19,511,000
16,307,000
17,210,000
Unusual Expense (Income)
NOPBT
7,605,000
10,974,000
10,095,000
NOPBT Margin
28.05%
40.23%
36.97%
Operating Taxes
1,247,000
1,248,000
2,077,000
Tax Rate
16.40%
11.37%
20.57%
NOPAT
6,358,000
9,726,000
8,018,000
Net income
5,665,000
23.37%
4,592,000
-26.23%
6,225,000
6,894.38%
Dividends
(3,809,000)
(3,709,000)
(3,605,000)
Dividend yield
3.74%
3.42%
3.93%
Proceeds from repurchase of equity
(768,000)
(1,087,000)
(377,000)
BB yield
0.75%
1.00%
0.41%
Debt
Debt current
1,798,000
2,273,000
1,516,000
Long-term debt
24,469,000
24,136,000
26,155,000
Deferred revenue
4,767,000
Other long-term liabilities
3,319,000
5,095,000
976,000
Net debt
17,840,000
17,534,000
18,533,000
Cash flow
Cash from operating activities
8,006,000
9,072,000
11,384,000
CAPEX
(585,000)
(728,000)
(579,000)
Cash from investing activities
(2,265,000)
(2,466,000)
(3,131,000)
Cash from financing activities
(5,125,000)
(6,469,000)
(8,877,000)
FCF
6,376,000
8,965,000
9,143,000
Balance
Cash
7,264,000
7,630,000
7,829,000
Long term investments
1,163,000
1,245,000
1,309,000
Excess cash
7,071,200
7,510,950
7,772,750
Stockholders' equity
16,249,000
15,659,000
16,403,000
Invested Capital
43,983,800
43,064,050
45,190,250
ROIC
14.61%
22.04%
17.19%
ROCE
14.45%
20.61%
17.61%
EV
Common stock shares outstanding
1,258,000
1,262,000
1,262,000
Price
81.01
-5.64%
85.85
18.23%
72.61
24.63%
Market cap
101,910,580
-5.94%
108,342,700
18.23%
91,633,820
24.53%
EV
119,666,580
125,845,700
110,161,820
EBITDA
10,298,000
13,077,000
12,145,000
EV/EBITDA
11.62
9.62
9.07
Interest
944,000
935,000
1,001,000
Interest/NOPBT
12.41%
8.52%
9.92%